CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today provided an update on its intellectual property portfolio. The Company’s intellectual property portfolio now contains over 575 issued patents and pending patent applications covering compositions of matter and methods of use for Idera’s technologies that include TLR-targeted immune modulatory oligonucleotides (IMO), gene silencing oligonucleotide (GSO) technology, and antisense technology. The Company also announced that it recently received the Patent Board’s top impact score and that it was recognized for the 12th consecutive time over the past four years by the Patent Board™ as one of the top 35 companies in the biotechnology field based on its technology and intellectual property strength.
